Figure 5
From: A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer
In vivo study of PPA@aPD-L1 against bladder cancer. (A) Illustration of in vivo study schedule. PBS, PP, PPA, PPA + aPD-L1 and PPA@aPD-L1 were administered respectively via tail vein 4 times after MB-49 cells implantation. (B) Survival of mice receiving different treatments (n = 5). (C) The images of tumors of mice receiving different treatments (n = 5). The tumor volume (D) and weight (E) of mice receiving different treatments (Mean ± SD, n = 5). (F) The tumor growth inhibition (TGI) value of mice receiving different treatments (Mean, n = 5). (G) The hematoxylineosin (H&E) staining of tumors of mice receiving different treatments. Scale bar = 1 mm. (H) Representative H&E staining images of main organs (heart, liver, kidney, lung and spleen) after treatment. Scale bar = 200 μm. Statistical significance was determined by one way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
